[Small molecules and biologicals].

Suppr

超能文献

作者信息

Smolen J

机构信息

Abt. für Rheumatologie, Universitätsklinik für Innere Medizin III, Währinger Gürtel 18-20, 1190, Wien, Österreich.

出版信息

Z Rheumatol. 2020 Apr;79(3):221-222. doi: 10.1007/s00393-020-00780-9.

DOI:10.1007/s00393-020-00780-9

PMID:32240355

Abstract

摘要

相似文献

[Small molecules and biologicals].

Z Rheumatol. 2020 Apr;79(3):221-222. doi: 10.1007/s00393-020-00780-9.

Rapid acidimetric determination of alum in alum-precipitated biologicals.快速酸碱滴定法测定明矾沉淀生物制品中的明矾

J Am Pharm Assoc Am Pharm Assoc. 1950 Sep;39(9):523-5. doi: 10.1002/jps.3030390917.

Using nuclear magnetic resonance spectroscopy to characterize biologicals.

Dev Biol (Basel). 2005;122:77-83.

[Biologicals and small molecules for rheumatoid arthritis].[用于类风湿性关节炎的生物制剂和小分子药物]

Z Rheumatol. 2020 Apr;79(3):223-231. doi: 10.1007/s00393-020-00766-7.

[Interaction between proteins and small and large molecules of biological systems].

Aggiorn Fisiol. 1951;2:41-78.

Post-marketing dosing changes in the label of biologicals.生物制品标签的上市后剂量调整。

Br J Clin Pharmacol. 2019 Apr;85(4):715-721. doi: 10.1111/bcp.13843. Epub 2019 Feb 16.

[Interchangeability of biological products in the Brazilian Unified National Health System (SUS): the main regulatory challenges].[巴西统一国家卫生系统（SUS）中生物制品的互换性：主要监管挑战]

Cad Saude Publica. 2019 Oct 14;35(10):e00053519. doi: 10.1590/0102-311X00053519. eCollection 2019.

Testing human biologicals in animal host resistance models.在动物宿主抗性模型中测试人类生物制品。

J Immunotoxicol. 2008 Jan;5(1):23-31. doi: 10.1080/15476910801897557.

Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice.从欧洲临床实践中收到的药物不良反应报告中识别生物制剂。

Clin Pharmacol Ther. 2019 Apr;105(4):962-969. doi: 10.1002/cpt.1310. Epub 2019 Jan 11.

Present systems and future needs for risk assessments of biologicals: the perspective of the regulator in the People's Republic of China.

Rev Sci Tech. 1995 Dec;14(4):1185-91. doi: 10.20506/rst.14.4.902.

本文引用的文献

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.在生物初治的活动性银屑病关节炎患者中比较依奇珠单抗和阿达木单抗的疗效和安全性的头对头比较：一项随机、开放标签、盲法评估试验的 24 周结果。

Ann Rheum Dis. 2020 Jan;79(1):123-131. doi: 10.1136/annrheumdis-2019-215386. Epub 2019 Sep 28.

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.乌帕替尼治疗甲氨蝶呤应答不足的类风湿关节炎患者的 III 期、双盲、随机对照研究结果。

Arthritis Rheumatol. 2019 Nov;71(11):1788-1800. doi: 10.1002/art.41032. Epub 2019 Aug 28.

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.乌帕替尼单药治疗对甲氨蝶呤应答不足的活动性类风湿关节炎患者（SELECT-MONOTHERAPY）：一项随机、安慰剂对照、双盲 3 期研究。

Lancet. 2019 Jun 8;393(10188):2303-2311. doi: 10.1016/S0140-6736(19)30419-2. Epub 2019 May 23.

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study.巴利替尼治疗达到持续疾病控制的类风湿关节炎患者的剂量减少：一项前瞻性研究的结果。

Ann Rheum Dis. 2019 Feb;78(2):171-178. doi: 10.1136/annrheumdis-2018-213271. Epub 2018 Sep 7.

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.巴利昔替尼治疗系统性红斑狼疮：一项双盲、随机、安慰剂对照、2 期临床试验。

Lancet. 2018 Jul 21;392(10143):222-231. doi: 10.1016/S0140-6736(18)31363-1.

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.乌帕替尼治疗对常规合成改善病情抗风湿药物应答不足的类风湿关节炎患者的安全性和疗效（SELECT-NEXT）：一项随机、双盲、安慰剂对照的 3 期临床试验。

Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.托法替布治疗对 TNF 抑制剂应答不足的银屑病关节炎患者。

N Engl J Med. 2017 Oct 19;377(16):1525-1536. doi: 10.1056/NEJMoa1615977.

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.托法替布单药治疗、托法替布联合甲氨蝶呤与阿达木单抗联合甲氨蝶呤治疗类风湿关节炎患者的疗效和安全性（ORAL Strategy）：一项 IIIb/IV 期、双盲、头对头、随机对照临床试验。

Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16.

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.巴利替尼与安慰剂或阿达木单抗治疗类风湿关节炎的疗效比较。

N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345.

Baricitinib in Patients with Refractory Rheumatoid Arthritis.巴瑞替尼治疗难治性类风湿关节炎患者的疗效。

N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验